Advancing Discovery Through Innovation
ACEA Biosciences is committed to providing innovative high performance technologies that advance scientific discovery and improve healthcare.
Employing noninvasive gold microelectrodes in diverse multiwell plate formats, our xCELLigence Real-Time Cell Analysis (RTCA) systems maximize the physiological relevance of data extracted from in vitro cellular assays by enabling label-free, real-time monitoring of cell proliferation, cell size/morphology, cell attachment quality, and cell invasion/migration. By continuously providing this data in the short (minutes to hours) and long (days to weeks) time regimes, RTCA provides a phenotypic view of cellular behavior at an unprecedented level of detail.
The NovoCyte Flow Cytometer system provides researchers who are performing cellular analysis access to innovative high performance flow cytometry, intuitive software, and versatile autosampler at affordable cost. NovoCyte is a customizable platform offering flexibility, high throughput and walk-away capabilities to meet current & future application needs.
ACEA Biosciences, Inc. is a privately owned biotechnology company pioneering in the development and commercialization of high-performance, cutting edge research instrumentation for life sciences. ACEA launched its first product for real-time, label-free cell-based assays based on a microelectronic readout in 2004. Today, the company has a product line of eight instruments which utilize this technology with different functionalities and throughputs, and enables different types of cell-based applications.
800+Citations in Peer Reviewed Publications
1700Products Placed Internationally